Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 19/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4869326 | 1.00 | GNRHR (0.63) | GNRHRCYP3A4CACNA1B | |
| SCHEMBL4869348 | 0.93 | GNRHR (0.66) | GNRHRCYP3A4 | |
| SCHEMBL4869340 | 0.93 | GNRHR (0.66) | GNRHRCYP3A4 | |
| SCHEMBL14006561 | 0.93 | GNRHR (0.61) | GNRHRCYP3A4CACNA1B | |
| SCHEMBL5132615 | 0.87 | GNRHR (0.79) | GNRHRCYP3A4 | |
| SCHEMBL14006554 | 0.86 | GNRHR (0.64) | GNRHRCYP3A4 | |
| SCHEMBL4868762 | 0.83 | GNRHR (0.59) | GNRHRCYP3A4 | |
| SCHEMBL4868782 | 0.83 | GNRHR (0.59) | GNRHRCYP3A4 | |
| SCHEMBL14006588 | 0.83 | GNRHR (0.59) | GNRHRCYP3A4 | |
| SCHEMBL14006596 | 0.83 | GNRHR (0.69) | GNRHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449489-B2 | Indolylalkylamino-methylidenecarbamate derivatives useful as GnRH antagonists | ASTRAZENECA AB (SE) | 2008-11-11 | — | — | US | claimed |
| US-20060258710-A1 | Indolylalkylamino-methylidenecarbamate derivatives useful as gnrh antagonists | ASTRAZENECA AB (SE) | 2006-11-16 | — | — | US | claimed |
| US-7449489-B2 | Indolylalkylamino-methylidenecarbamate derivatives useful as GnRH antagonists | ASTRAZENECA AB (SE) | 2008-11-11 | — | — | US | disclosed |
| US-20060258710-A1 | Indolylalkylamino-methylidenecarbamate derivatives useful as gnrh antagonists | ASTRAZENECA AB (SE) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258710-A1 | Indolylalkylamino-methylidenecarbamate derivatives useful as gnrh antagonists | GNRHR, GHRHR, PRLHR | GNRHR 1/4885CYP3A4 2120/4885CACNA1B 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.